Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial

Página do item simplificado
dc.contributor.authorMattar, Andre [UNIFESP]
dc.contributor.authorLogullo, Angela Flavia [UNIFESP]
dc.contributor.authorFacina, Gil [UNIFESP]
dc.contributor.authorNonogaki, Suely
dc.contributor.authorSoares, Fernando Augusto
dc.contributor.authorGebrim, Luiz Henrique [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionAdolfo Lutz Inst
dc.contributor.institutionAntonio Prudente Fdn
dc.date.accessioned2016-01-24T14:16:41Z
dc.date.available2016-01-24T14:16:41Z
dc.date.issued2011-05-01
dc.description.abstractThe objective of this study was to compare Ki-67, Bcl-2, Bax, Bak, ER, and PgR expression in postmenopausal women with ER-positive invasive breast cancer (IBC) before and after short-term hormone therapy (HT) with either tamoxifen or anastrozole in order to identify a possible biomarker profile associated with hormone resistance.Fifty-eight patients with palpable IBC were assigned to receive neoadjuvant therapy with either anastrozole, placebo, or tamoxifen for 26 days prior to surgery. Tissue microarray blocks were constructed from pre- and post-treatment biopsy samples and used for immunohistochemical analysis. Biomarker (Ki-67, Bcl-2, Bax, Bak, ER, and PgR) levels were assessed semiquantitatively using the Allred score. A statistical analysis was performed using general estimating equations (GEE) and analysis of variance (ANOVA) with a significance level of 0.05.There was a significant reduction in PgR scores from baseline (mean, 4.22) to post-treatment (mean, 1.94) in the anastrozole group, but only a non-significant trend toward an increase in PgR scores was found in the tamoxifen group. There was a significant reduction in Ki-67 scores from baseline (mean, 3.61) to post-treatment (mean, 2.56) in the anastrozole group (P = 0.01), but only a non-significant trend toward a reduction in Ki-67 scores was found in the tamoxifen group.There was a significant reduction in PgR and Ki-67 expression in the group treated with anastrozole. in the present study, the short-term HT was not associated with changes in apoptosis-related protein levels, regardless the type of drug used.en
dc.description.affiliationFed Univ São Paulo UNIFESP, Dept Gynecol, BR-04024002 São Paulo, Brazil
dc.description.affiliationFed Univ São Paulo UNIFESP, Dept Pathol, BR-04024002 São Paulo, Brazil
dc.description.affiliationAdolfo Lutz Inst, Lab Immunohistochem, São Paulo, Brazil
dc.description.affiliationAntonio Prudente Fdn, Dept Pathol, São Paulo, Brazil
dc.description.affiliationUnifespFed Univ São Paulo UNIFESP, Dept Gynecol, BR-04024002 São Paulo, Brazil
dc.description.affiliationUnifespFed Univ São Paulo UNIFESP, Dept Pathol, BR-04024002 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent897-905
dc.identifierhttp://dx.doi.org/10.1007/s00432-010-0950-4
dc.identifier.citationJournal of Cancer Research and Clinical Oncology. New York: Springer, v. 137, n. 5, p. 897-905, 2011.
dc.identifier.doi10.1007/s00432-010-0950-4
dc.identifier.issn0171-5216
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33664
dc.identifier.wosWOS:000289440900017
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectAnastrozoleen
dc.subjectBreast canceren
dc.subjectKi-67en
dc.subjectEstrogen receptoren
dc.subjectProgesterone receptoren
dc.subjectShort-term hormone therapyen
dc.titleShort-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trialen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos